Manipal Hospital Yeshwanthpur Leads the Charge as Heart Attacks in Young Indians Reach Crisis Levels
Striking recent investigations into sudden cardiac arrests and deaths in Hassan District, Karnataka, confirm that one-third of these fatalities were among auto and cab drivers—a profession increasingly recognized as highly vulnerable due to, long hours, erratic schedules, and hazardous environmental exposures. This stark reality has highlighted the need for proactive heart health education and life-saving interventions for communities at risk, especially transport workers who spend most of their day on the road.
In this context, CPR (Cardiopulmonary Resuscitation) training has never been more critical. During a sudden cardiac arrest episode, administering immediate CPR can dramatically increase the victim's chance of survival while they await emergency care. Immediate intervention keeps blood and hope flowing until professional help arrives, making every trained community member a potential lifesaver.
CPR Awareness Drive: A Step Toward Safer Streets: In response to this urgent public health need, Manipal Hospital Yeshwanthpur organized a CPR demonstration and heart health awareness session for over 20 auto rickshaw drivers, led by Mr. Rudramurthy, General Secretary of the Auto Rickshaw Drivers' Union (ARDU). Guided by Dr Prasanna Katti, Senior Consultant – Interventional Cardiology and Dr. Eshwari Devi, Registrar, Cardiology, at Manipal Hospital Yeshwanthpur, the event aimed to equip participants with tangible, life-saving skills.
The session included practical demonstrations using adult male, female, and infant (baby) mannequins, ensuring that participants were equipped to perform CPR on individuals of any age or gender during real-life emergencies. Speaking on the significance of hands-on demonstration, Dr. Eshwari Devi stated, 'Learning to perform a CPR and helping a person in a critical condition makes a huge difference in saving a life. Every individual or the first responder trained in CPR becomes a potential hero and a lifesaver for the community.'
In a move to strengthen emergency response readiness, both doctors not only presided over the event and led CPR training but also personally distributed and affixed Manipal SOS – QR Code stickers to each participant's auto rickshaw. The SOS QR code is Manipal Hospitals innovative technology that enables the first-responder or caregiver to seek swift ambulance support during emergencies by simply scanning the QR code, which is equipped with precise location detection. This ensures that the victim receives care within the critical 'Golden Hour'—a move that can make all the difference in survival outcomes.
Equipping the participants with further knowledge on general health, wellness, and heart health in particular, Dr. Katti shared health tips tailored for the demanding routines of auto drivers. He discussed the dangers of smoking, the importance of regular physical activity, a balanced diet, and recognizing early signs of heart trouble. 'Quit smoking and drinking, also exercise regularly to prevent the chances of a heart attack. Everybody must learn CPR and try their best to save someone who is having a heart attack,' he stated.
Through this initiative, Manipal Hospital Yeshwanthpur, reaffirms its commitment to preventive care, community outreach, and empowering everyday heroes with the knowledge and skills that can save lives. Manipal Hospitals continues to lead the charge in making advanced cardiac care more accessible, not just inside hospital walls, but out in the community where it matters most.
For more information, please visit: https://www.manipalhospitals.com/
Photo: https://mma.prnewswire.com/media/2733288/MANIPAL_CPR_Awareness_1.jpgPhoto: https://mma.prnewswire.com/media/2733289/MANIPAL_CPR_Awareness_2.jpg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
7 hours ago
- Malaysian Reserve
BioLab Holdings, Inc. Launches Its Largest Clinical Trial to Date Evaluating Human Placental Membrane Products
Study Will Compare Four Amnion-Based Therapies Plus Standard of Care to Standard of Care Alone in Chronic Wound Management PHOENIX, July 31, 2025 /PRNewswire/ — BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in regenerative wound care, has initiated its most comprehensive clinical trial to date. The multicenter, prospective, randomized controlled study will evaluate the efficacy of four human placental membrane (HPM) products in combination with standard of care (SOC) compared to SOC alone in the treatment of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The trial, formally titled 'A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers (BIOCAMP),' will enroll 650 subjects across up to 30 clinical sites nationwide. 'This study represents a major milestone in our commitment to advancing wound care through rigorous clinical research,' said Dr. Marshall Medley, chief medical officer at BioLab. 'By evaluating our full suite of amnion-based products in a real-world setting, we aim to provide clinicians with robust data to guide treatment decisions for patients with chronic wounds.' Participants will be randomized to receive one of four BioLab products—Tri-Membrane Wrap™ (HPM-1), Membrane Wrap™ (HPM-2), Membrane Wrap-Lite™ (HPM-3), or Membrane Wrap-Hydro™ (HPM-4)—in addition to SOC, or SOC alone. Treatments will be applied weekly for up to 12 weeks or until complete wound closure is achieved and confirmed two weeks later. Optional weekly visits will allow for dressing changes in both study arms. The study is designed to capture real-world clinical outcomes and support the growing body of evidence for the use of placental-derived allografts in chronic wound management. For more information on BioLab Holdings, Inc. and its regenerative wound care solutions, visit About BioLab Holdings, Holdings, Inc. is a Phoenix-based medical manufacturer focused on wound healing and regenerative medicine. Its product portfolio includes Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™ and Membrane Wrap – Hydro™, all derived from human amniotic membrane. These minimally manipulated allografts are designed to preserve the tissue's natural properties and support healing. BioLab is committed to delivering safe, high-quality products through innovation, education and exceptional customer service. Learn more at Contact: Kwyn LowePhone: 406.314.5120Email: kwyn@
Malaysian Reserve
7 hours ago
- Malaysian Reserve
FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) witho
FDA approval is based on phase 3 trial data (explorer8), which established the safety and efficacy of Alhemo® (concizumab-mtci) injection in people 12 years and older with hemophilia A or B (HA/HB) without inhibitors1 Results showed a 79% reduction in annualized bleeding rate (ABR) in patients with HB without inhibitors and an 86% reduction in patients with HA without inhibitors, respectively, using Alhemo® prophylaxis compared to no prophylaxis2 Alhemo® was the first subcutaneous injectable pen of its kind for patients living with HA and HB with inhibitors and is now approved for those living without inhibitors1 PLAINSBORO, N.J., July 31, 2025 /PRNewswire/ — Novo Nordisk announced today that the US Food and Drug Administration (FDA) approved Alhemo® (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors, expanding on the December 2024 approval for HA/HB with inhibitors.1,2,3 Currently, many treatments for HA/HB without inhibitors are administered via intravenous infusions.2 With this approval, Alhemo® now offers a subcutaneous injection treatment option for this population.1 'The FDA approval of an expanded indication for Alhemo® marks a meaningful step forward for people with hemophilia A or B without inhibitors who are looking for a new prophylaxis treatment option,' said Anna Windle, PhD, Senior Vice President, Clinical Development, Medical & Regulatory Affairs, Novo Nordisk. 'By building on the initial indication for Alhemo® for those with hemophilia with inhibitors—an especially significant development in hemophilia B where challenges still exist despite advanced treatment options—Novo Nordisk continues its 35+ year legacy in rare bleeding disorders to continue to help address the unmet needs of this community.' Alhemo® is designed to block a protein called tissue factor pathway inhibitor (TFPI), which stops blood from clotting. By inhibiting TFPI, Alhemo® improves the production of thrombin, which helps to clot the blood and prevent bleeding, when clotting factors VIII and IX are missing or deficient regardless of inhibitor status.4,5 'For people living with hemophilia, it is important to continually monitor and discuss bleed control with their healthcare professional,' said Allison P. Wheeler, MD, Scientific Director, Washington Center for Bleeding Disorders, Seattle, WA. 'With today's approval of Alhemo® for hemophilia A or B without inhibitors, more people living with these rare blood disorders now have a daily prophylaxis option that may help decrease their bleeding rates.' The primary objective of the pivotal phase 3 explorer8 trial was to compare the number of treated spontaneous and traumatic bleeding episodes, as measured by the ABR, in patients aged 12 years and older with HA/HB without inhibitors, receiving Alhemo® prophylaxis versus no prophylaxis (on demand Factor VIII/Factor IX treatment).2 The study showed a statistically significant reduction in ABR of 79% for HB patients (ABR ratio: 0.21; 95% CI: 0.10–0.45; p<0.0001) and 86% for HA patients (ABR ratio: 0.14; 95% CI: 0.07–0.29; p<0.0001). Additionally, notable reductions in the average and median ABRs further reinforced the efficacy of Alhemo® prophylaxis in reducing bleeds across both patient groups, with an average ABR of 3.1 (1.9-5.0) and a median ABR of 1.6 (0.0-4.8) for HB patients, compared to 14.8 (8.1-26.9) and 14.9 (3.3-22.1), respectively, and an average ABR of 2.7 (1.6-4.6) and median ABR of 2.9 (0.0-5.2) for HA patients, compared to 19.3 (11.3-33.0) and 19.6 (17.3-30.4), respectively. In the study, the most common adverse reactions reported in ≥5% of patients randomized to receive Alhemo® were injection site reactions (7%) and headache (7%).1 Alhemo® is provided in prefilled, premixed pens for subcutaneous injection (60 mg/1.5 mL, 150 mg/1.5 mL, or 300 mg/3 mL) via thin 32 gauge, 4 mm needles, which are provided separately, offering an additional treatment choice for patients with hemophilia with inhibitors – and now without inhibitors – to further customize their care. About the explorer8 studyExplorer8 is a phase 3 clinical trial that evaluated the efficacy and safety of Alhemo® for adults and pediatric patients 12 years of age and older living with hemophilia A or B (HA/HB) without inhibitors.2 In explorer8, among the 156 males with HA/HB included in the trial, 63 were randomly assigned in a 1:2 ratio to receive no prophylaxis (arm 1, n=21), or Alhemo® prophylaxis (arm 2, n=42).2,6 The median duration of treatment was 24.1 weeks in arm 1 (no prophylaxis) and 32.1 weeks in arm 2 (Alhemo® prophylaxis).The initial loading dose of Alhemo® was 1 mg per kilogram of body weight, followed by 0.2 mg per kilogram daily, and potentially individualized on the basis of concizumab-mtci plasma concentration as measured at week 4.1,2 Efficacy was evaluated separately in HA patients without inhibitors and in HB patients without inhibitors when all patients in arms 1 and 2 had completed the main part of the trial (at least 24 or at least 32 weeks, respectively), based on the number of treated bleeding episodes comparing Alhemo® prophylaxis and no prophylaxis.1 About Alhemo® (concizumab-mtci) Alhemo® is a tissue factor pathway inhibitor (TFPI) antagonist. By inhibiting the TFPI, Alhemo® enhances factor Xa (FXa) production during the initiation phase of coagulation, leading to improved thrombin generation and clot formation in patients with hemophilia A or B (HA/HB) with or without inhibitors. The effect of Alhemo® is not influenced by the presence of inhibitory antibodies to FVIII or FIX and Alhemo® does not induce or enhance the development of direct inhibitors to FVIII or FIX. Alhemo® is approved as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with HA/HB with or without inhibitors in the US.1 What is Alhemo®?Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A or B with or without factor VIII or IX inhibitors. It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age Important Safety Information What is the most important information I should know about Alhemo®? It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding Your HCP may prescribe factor VIII, factor IX, or bypassing agents during treatment with Alhemo®. Carefully follow your HCP's instructions regarding when to use on-demand factor VIII, factor IX, or bypassing agents and the recommended dose and schedule for breakthrough bleeds Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®. Before using Alhemo®, tell your HCP about all of your medical conditions, including if you: Have a planned surgery. Talk to your HCP about when to stop using Alhemo® and when to start it again if you have a planned surgery Are pregnant, breastfeeding, or plan to become pregnant or breastfeed. It is not known if Alhemo® may harm your unborn baby or if Alhemo® passes into your breast milk Your HCP may do a pregnancy test before you start treatment with Alhemo® Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment Your HCP may do a pregnancy test before you start treatment with Alhemo® Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements. What are the possible side effects of Alhemo®?Alhemo® may cause serious side effects, including: Blood clots (thromboembolic events). Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision Allergic reactions. Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat The most common side effects of Alhemo® include: bruising, redness, bleeding, itching, rash or lump at the injection site, headache, and hives. These are not all the possible side effects of Alhemo®. Call your doctor for medical advice about side effects. Please click HERE for Alhemo® Prescribing Information and Medication Guide About hemophiliaHemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.7 It is estimated to affect approximately ~800,000 people worldwide.8 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing. Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and hemophilia B is caused by a missing or defective clotting Factor IX (FIX).7 Hemophilia is often treated by replacing the missing clotting factor via intravenous infusions, also known as replacement therapy.8 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D, and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. References Alhemo® (concizumab-mtci) injection, for subcutaneous use [package insert]. Plainsboro, NJ: Novo Nordisk Inc. Chowdary P., et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Hematology. 2024;11:e891-904. Novo Nordisk. FDA approves drug to prevent or reduce the frequency of bleeding episodes for patients with hemophilia A with inhibitors or hemophilia B with inhibitors. Accessed May 2025. Available at Shapiro AD. Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Adv. 2021;5(1):279. Matsushita T, Shapiro A, Abraham A, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023; 389(9): 783-794. Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors (explorer8). Accessed May 2025. Available at MedlinePlus. Hemophilia. Accessed May 2025. Available at World Federation of Hemophilia. Annual Global Survey 2023. Accessed July 2025. Further information Liz Skrbkova (US)+1 609 917 0632 (Mobile)USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Alhemo® is a registered trademark of Novo Nordisk Health Care AG. Novo Nordisk is a registered trademark of Novo Nordisk A/S.© 2025 Novo Nordisk All rights reserved. US25AHM00187 July 2025
Malaysian Reserve
11 hours ago
- Malaysian Reserve
Meridian and the Centene Foundation Announce $1 Million Grant to the Food Bank Council of Michigan
The partnership aims to expand access to fresh food and enhance health outcomes in rural southwest Michigan food deserts DETROIT, July 31, 2025 /PRNewswire/ — Meridian Health Plan of Michigan, Inc. ('Meridian'), a leading managed care organization in Michigan, and the Centene Foundation, the philanthropic arm of Centene Corporation (NYSE: CNC), announced today a $1 million grant to the Food Bank Council of Michigan (FBCM), a cooperative network of the state's regional food banks dedicated to alleviating hunger and food insecurity. The grant will support efforts in Prosperity Region 8, which includes Berrien, Branch, Calhoun, Cass, Kalamazoo, St. Joseph and Van Buren counties to upgrade current food pantries, equipping community members with food as medicine interventions, and providing technological support to future In Lieu of Services (ILOS) implementation. Additionally, the two-phased program will fund a fresh food pharmacy program at a federally qualified health center to support patients with diet-sensitive chronic conditions while offering health coaching supporting. 'Research shows that hunger, health and well-being are deeply connected,' said Patty Graham, Meridian Plan President and CEO. 'People who are food insecure are affected by diet-sensitive chronic diseases such as diabetes and high blood pressure. By focusing on a proactive coordinated approach, this partnership will increase food access, remove transportation barriers and create a holistic pathway to address the root causes of health problems and health disparities in rural Michigan.' Phase One will designate and upgrade two existing food pantries to serve as Nourish MI Pantries, a model developed by the Food Bank Council of Michigan in collaboration with regional food banks, funders, and healthcare partners to support and enhance community pantries across the state. The model offers a shared standard that expands access to fresh, nutritious foods, enhances client experience, and supports partnerships in health and equity. Participation in the model reflects a commitment to practices like client-choice shopping, fresh and frozen food availability, set hours, and a wide variety of healthy options. Pantries may also receive the ILOS Certified designation, allowing them to serve enrollees of Michigan's Medicaid Health Plans (MHPs) participating in the Comprehensive Health Care Program (CHCP) Nourish MI Pantry Packs, a curated food pack that aligns with healthcare and nutrition goals. The Phase One pantries will be equipped to deliver food as medicine interventions supported by local food bank development teams to implement a long-term plan for sustaining access to fresh food. Support could include the purchase of food, cold storage (such as refrigerators or freezers), shelving and other storage supplies, and technological support such as computers or tablets to support future In Lieu of Services (ILOS) implementation. The food banks will also provide technical assistance as needed to help the pantries effectively support ILOS patients. The initiative aims to strengthen local food access while also building capacity for ILOS operations for all participating Medicaid health plans. Phase Two, set to begin in 2026, will expand the program, designating and upgrading five additional Nourish MI Pantries across the same region. It will also fund the Fresh Food Pharmacy (FFP) program at Grace Health, a federally qualified health center in Battle Creek. The funding for FFP helps eligible members with diet-sensitive chronic conditions access nutritious food and health education, while also supporting efforts to build a long-term sustainability strategy for the program. Eligible patients of Grace Health with chronic conditions can shop at the on-site pantry and participate in health coaching support. Following the COVID-19 pandemic, the number of Michiganders facing food insecurity has continued to grow and is especially prevalent in rural communities, where many travel long distances to get fresh produce because of limited grocery stores and limited public transit. This, along with other factors such as low income and few job prospects, can lead to food insecurity, which can adversely impact health and well-being. More than 1.4 million people are food insecure in Michigan, according to Feeding America's Map the Meal Gap, and more than 378,000 of them are children. 'At the Food Bank Council of Michigan, our mission is to create a food-secure state through advocacy, collaboration and innovative solutions,' said Dr. Phil Knight, Food Bank Council of Michigan Executive Director. 'This partnership with Meridian and the Centene Foundation exemplifies that commitment by bringing lasting, fresh food access to rural communities in a way that's both sustainable and designed to improve health outcomes. Together, we're not only addressing hunger today, but laying groundwork to solve it for tomorrow.' By investing in the sustainability of the Fresh Food Pharmacy program and partnering with local pantries to strengthen and designate them as Nourish MI Pantries aligned with food as medicine principles, Meridian and the Centene Foundation further their commitment to bring fresh food year-round to rural areas. This includes areas of the state where residents face access barriers ensuring a healthier, more food-secure future for all Michiganders through this three-year partnership. About Meridian Health Plan of Michigan, provides government-sponsored managed care services to families, children, seniors and individuals with complex medical needs primarily through Medicaid (Meridian), Medicare Advantage and Medicare Prescription Drug Plans (WellCare), Medicare-Medicaid Plans (MeridianComplete) and the Health Insurance Marketplace (Ambetter from Meridian). Meridian is a Centene Corporation company. For more information, visit About the Centene FoundationThe Centene Foundation (the 'Foundation'), a private nonprofit focused on investing in economically challenged communities, is the philanthropic arm of Centene Corporation (NYSE: CNC) ('Centene'). The Foundation supports projects and initiatives strategically aligned with Centene's mission-driven culture and enhances the work Centene is doing to remove the barriers to wellness underserved and low-income populations face. The Foundation is committed to addressing drivers of health and improving health equity in three distinct areas of focus: healthcare, social services and education. To learn more, visit the Centene Foundation's website. About Food Bank Council of Michigan The Food Bank Council of Michigan (FBCM), founded in 1984, leads a unified effort to end hunger across the state. By addressing the root causes of hunger, FBCM raises awareness, advocates for policies that protect those in need, conducts in-depth research to find sustainable solutions, and provides thought leadership and resources to Michigan's food banks. Working with its network of regional food banks, over 2,800 hunger relief agencies, private companies, farmers, state and federal officials, and other allies, FBCM strives to ensure that no Michigander goes without food. To learn more about the Food Bank Council of Michigan's role in eliminating food insecurity, visit or call 517-485-1202.
